oligopeptide linker method of this invention. Monoclonal antibody L8A4 was labeled using the oligopeptide linker as follows. The peptide α-N-Ac-D-Lys-D-Arg-D-Tyr-D-Arg-D-Arg (KRYRR) (SEQ ID NO:3) was obtained from a custom synthesis laboratory and labeled with ^{125}I using the Iodogen method. Reverse phase HPLC was used to isolate ^{125}I-labeled KRYRR (SEQ ID NO:3) in >97% yield, and the labeled peptide was activated by reaction with sulfo-SMCC at room temperature for 30 min. Murine anti-EGFRvIII mAb L8A4 was reacted with 2-imino thiolane to generate free thiol groups and then reacted with activated ^{125}I-labeled peptide-L8A4. The conjugate was isolated over a Sephadex G-25-PD10 column. The yield was about 35%.

Please replace the Sequence Listing at the end of the application with the substitute sequence listing (pages 1-2), which is appended pursuant to 37 C.F.R. § 1.825(a). A substitute copy of the computer readable form is enclosed pursuant to 37 C.F.R. § 1.825(b). The undersigned hereby certifies that the content of the sequence listing and the computer-readable form are the same. The substitute sequence listing is supported by the specification and does not introduce new matter.

REMARKS

Claims 1-21 and 44-47 are pending in the application.

The Amendments

The specification has been amended to correct inadvertent errors and omissions found during the prosecution of U.S. divisional patent application serial no. 09/558,150. Specifically, the paragraph beginning on page 28, line 25 and ending on page 29, line 6 has been replaced with a new paragraph to add reference to the Sequence Listing and to